Thermo Fisher Scientific Inc. $TMO Shares Sold by EFG Asset Management Americas Corp.

EFG Asset Management Americas Corp. lowered its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 47.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,378 shares of the medical research company’s stock after selling 4,784 shares during the period. EFG Asset Management Americas Corp.’s holdings in Thermo Fisher Scientific were worth $2,181,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of TMO. Brighton Jones LLC raised its holdings in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the last quarter. Revolve Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares in the last quarter. J.W. Cole Advisors Inc. raised its stake in Thermo Fisher Scientific by 113.5% in the 1st quarter. J.W. Cole Advisors Inc. now owns 3,828 shares of the medical research company’s stock valued at $1,905,000 after purchasing an additional 2,035 shares during the last quarter. Proficio Capital Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 4.0% during the 1st quarter. Proficio Capital Partners LLC now owns 1,525 shares of the medical research company’s stock worth $759,000 after purchasing an additional 59 shares during the last quarter. Finally, Oak Thistle LLC acquired a new position in shares of Thermo Fisher Scientific in the first quarter valued at approximately $4,248,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Michel Lagarde sold 4,638 shares of the business’s stock in a transaction dated Thursday, November 13th. The shares were sold at an average price of $594.42, for a total value of $2,756,919.96. Following the completion of the sale, the chief operating officer owned 23,480 shares of the company’s stock, valued at approximately $13,956,981.60. The trade was a 16.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 51,845 shares of company stock worth $28,956,952 over the last 90 days. 0.33% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several analysts have commented on the company. Raymond James Financial restated an “outperform” rating and issued a $535.00 price target (up previously from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, October 8th. Barclays increased their target price on Thermo Fisher Scientific from $585.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Evercore ISI upped their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Finally, Cowen reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Nineteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $601.65.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $573.39 on Thursday. The company has a market cap of $215.43 billion, a P/E ratio of 33.12, a PEG ratio of 3.27 and a beta of 0.82. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $610.97. The business’s 50-day simple moving average is $533.28 and its 200 day simple moving average is $471.15. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same quarter last year, the company earned $5.28 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has initiated a stock buyback plan on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.